Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Zelda Therapeutics makes significant progress in medicinal cannabis research programs

Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter.

Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients.

The study is set to be conducted at the USA-based Children's Hospital of Philadelphia, and Zelda says it is a key milestone in ongoing medical cannabis research in a clinical environment.

The group has also expanded its pre-clinical pancreatic cancer research programme with Curtin University.

The study focuses on live animal studies to investigate the effect of a range of the group's formulations in combination with existing chemotherapy agents.

Zelda says animal research is a major precursor to future human clinical trials.

During the last quarter, the group announced the initiation of a new pre-clinical research programme exploiting the potential for certain cannabinoids formulations to reduce the impact of diabetes-associated cognitive decline.

This study is also being conducted in partnership with Curtin University.

Zelda says it has made "excellent" progress on its clinical trial that is investigating the effect of medicinal marijuana on people with chronic insomnia symptoms.

Outside of the research and development sphere, Zelda has been approved for trading on the OTCQB Venture Market in the USA under the symbol ZLDAF.

The OTCQB is a US-based trading platform for early-stage and developing USA and international companies.

Through this new market, the group aims to grow its access to the US investment community.

Executive chairman Harry Karelis said he was pleased with Zelda's performance in the March quarter.

"We have made an excellent start to 2018 with significant progress on multiple research fronts autism, pancreatic cancer, insomnia and now cognitive decline," says Karelis.

"We firmly believe our approach is the correct strategy in an environment where regulators continue to tighten their oversight on groups making unsubstantiated claims for cannabinoid products."

Shares in Zelda Therapeutics closed at $0.12 per share on 27 April 2018.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How communications technology can raise the bar on customer service, employee experience
Partner Content
From capturing feedback early to providing messages with a higher rate of cut-through, ...
Advertisement

Related Stories

Car subscription software company Loopit eyes global markets after $3.6m seed round

Car subscription software company Loopit eyes global markets after $3.6m seed round

In a bid to enter new global markets and capitalise on the growing ...

Fashion-tech startup Citizen Wolf uses data to tailor tees, alleviate landfill

Fashion-tech startup Citizen Wolf uses data to tailor tees, alleviate landfill

As a consequence of our addiction to fast fashion, Australia sends ...

Apollo to divest large share of motorhome fleet to get Tourism Holdings merger over the line

Apollo to divest large share of motorhome fleet to get Tourism Holdings merger over the line

In an effort to appease Australian and New Zealand regulator concer...

Dexus awards John Holland building contract in $2.1b Waterfront Brisbane project

Dexus awards John Holland building contract in $2.1b Waterfront Brisbane project

After securing an $830 million contract from Dexus (ASX: DXS), Melb...